Patent dispute solved, new multi-year licencing deal agreed.
Target is implicated in a number of nervous system diseases.
This week’s news
Candidates slow down motor neurone death in patient samples.
But biotech still has several hurdles to clear – including Roche’s rival.
For the first time, FDA approves drug on the basis of biomarkers, rather than location.
Partnership to create voice-first solution letting researchers create and manage care plans.
Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
Competitor to Amgen’s Epogen also moves closer to market
MSD may have abused dominant market position, says CMA.
New drug will be sold at around 30% discount to rivals.
Deal looks to measure impact of ‘Lifestyle Therapy’ on diabetes treatment.
Results give advantage to Boehringer/Lilly’s Jardiance.
Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
Parties take out rival ads as social care funding row escalates.
Chiesi takes on Seretide and other lung drugs with Trimbow.
Italian pharma gets EU rights to Seloken.